Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan

被引：0
|
作者：
Gonzalez-Baron, M. [1 ]
Blanco, M. [1 ]
Feliu, J. [1 ]
Gomez, C. [1 ]
Casado, E. [1 ]
Castro, J. [1 ]
Belda-Iniesta, C. [1 ]
Garrido, M. [1 ]
Aguayo, C. [1 ]
Campos, M. A. [1 ]
机构：
[1] Hosp La Paz, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14600
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan
    Palshof, Jesper Andreas
    Christensen, Troels Dreier
    Poulsen, Tim Svendstrup
    Jensen, Benny Vittrup
    Linnemann, Dorte
    Schou, Jakob Vasehus
    Pfeiffer, Per
    Yilmaz, Mette K. N.
    Christensen, Ib Jarle
    Hogdall, Estrid V.
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [23] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [24] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [25] Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer
    Hebbar, Mohamed
    Di Fiore, Frederic
    Conroy, Thierry
    Giraud, Claire
    Gasnault, Laurent
    Fournier, Charles
    Pereira, Renata
    Bouche, Olivier
    Fournier, Peggy
    Deligny, Nathalie
    Joly, Jean-Paul
    Maes, Patricia
    Rad, Emilia
    Michel, Pierre
    Adenis, Antoine
    ONCOLOGY, 2007, 73 (3-4) : 185 - 191
  • [26] Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin INVITED COMMENTARY
    Chang, George J.
    DISEASES OF THE COLON & RECTUM, 2009, 52 (06) : 1152 - 1153
  • [27] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, P.
    Nielsen, D.
    Bjerregaard, J.
    Qvortrup, C.
    Yilmaz, M.
    Jensen, B.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1141 - 1145
  • [28] Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada
    Jerzak, Katarzyna J.
    Berry, Scott
    Ko, Yoo-Joung
    Earle, Craig
    Chan, Kelvin K. W.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 2162 - 2167
  • [29] EFFICACY AND SAFETY OF CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-REFRACTORY ELDERLY PATIENTS (>65 YEARS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 195 - 195
  • [30] Efficacy and safety of Cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ONKOLOGIE, 2010, 33 : 174 - 174
12345